PROSPECTIVE EVALUATION OF THE NATURAL COURSE OF
IDIOPATHIC SUBCLINICAL HYPOTHYROIDISM IN
CHILDHOOD AND ADOLESCENCE

Malgorzata Wasniewska 1, Mariacarolina Salerno 2, Alessandra Cassio 3,
Andrea Corrias 4, Tommaso Aversa 1, Giuseppina Zirilli 1, Donatella
Capalbo 2, Milva Bal 3, Alessandro Musa 4, Filippo De Luca 1

1 Department of Pediatrics, University of Messina, Messina, Italy;
2 Department of Pediatrics, University “Federico II”, Naples, Italy;
3 Department of Pediatrics, University of Bologna, Bologna, Italy;
4 Department of Pediatrics, University of Turin, Turin, Italy;

Corresponding author: Prof. Filippo De Luca (M.D.), Dipartimento di
Scienze Pediatriche Mediche e Chirurgiche, Policlinico Universitario di
Messina, Via Consolare Valeria, 98123 Messina, Italy

Tel: ++39 090 2213157, Fax: ++39 090 2212143,
e-mail: wasniewska@yahoo.it

Short running title: evolution of idiopathic subclinical hypothyroidism

The word count 4336
ABSTRACT

Objective: To prospectively evaluate the course of subclinical hypothyroidism (SH) in children and adolescents with no underlying diseases and no risk factors which might interfere with the progression of SH.

Design: Clinical status, thyroid function and autoimmunity were prospectively evaluated at entry and after 6, 12 and 24 months in 92 young patients (mean age 8.1 ± 3.0 years) with idiopathic SH.

Results: During the study mean TSH levels showed a trend towards a progressive decrease while FT4 levels remained unchanged. On overall 38 patients normalized their TSH (Group A): sixteen between 6 and 12 months and twenty-two between 12 and 24 months. Among the remaining 54 patients, the majority maintained TSH within the baseline values (Group B), whereas 11 exhibited a further increase of TSH above 10 mU/l (Group C). Baseline TSH and FT4 levels were similar in the patients who normalized TSH compared with those with persistent hyperthyrotropinemia. Even in the patients of Group C, both TSH and FT4 at entry were not different with respect to those of Group A and B. No patients showed any symptoms of hypothyroidism during follow-up and no changes of both height and body mass index were observed throughout the observation period.

Conclusions: a) the natural course of TSH values in a pediatric population with idiopathic SH is characterized by a progressive decrease over time; b) the majority of patients (88%) normalized or maintained unchanged their TSH; c) TSH changes were not associated with either FT4 values or clinical status or auxological parameters.
**Abbreviations:**

SH – subclinical hypothyroidism

US – ultrasonography

TPAAb – thyroid peroxidase antibodies

H – height

BMI – body mass index

SDS – SD scores

TSHR – TSH receptor
INTRODUCTION

Subclinical hypothyroidism (SH) is a condition of moderate thyroid failure characterized by normal circulating levels of thyroid hormones with mildly elevated TSH serum concentrations. SH is a common clinical problem in adulthood and elderly, whereas its prevalence is distinctly lower in children and adolescents (1).

The natural course of SH in aged patients has been reported to be characterized by frequent normalization of TSH elevation, whereas the risk of progression to overt hypothyroidism was significantly greater in the ones with high TSH concentrations at baseline (2). Data concerning the natural evolution of SH in childhood and adolescence are very scanty. According to one of the few available follow-up studies on juvenile SH, this may be a benign and remitting process with a very low risk of evolution towards frank hypothyroidism (3).

All the available reports on the spontaneous evolution of SH in both aged and young patients have been based to now on unselected study populations including also patients with either thyroid disorders or other pathological causes that are well known to be able to affect SH development and evolution (1,2,4-7).

In the present multicenter study we have prospectively investigated during a two-year follow-up the spontaneous changes of TSH and FT4 values in a pediatric population consisting of only patients with “idiopathic” SH, i.e. without nonthyroidal diseases and with no previous thyroid disorders or therapies affecting thyroid gland. Aim of our study design was to prospectively evaluate for the first time the natural course of SH in children
and adolescents with no underlying diseases and no risk factors which might interfere with the progression of SH.

PATIENTS AND METHODS

Study population and design

Ninety-two selected patients (50 boys) with “idiopathic” SH were enrolled according to well-assessed inclusion and exclusion criteria. All of them were younger than 15 years (mean age 8.1 ± 3.0 yrs; range 5.0 – 14.9) and had been referred to our pediatric endocrine clinics from the community by their pediatricians because of the incidental finding of elevated TSH concentrations in their usual annual check-up, that included also TSH measurement. Sixty-seven of them were prepubertal (72.8%) and 25 were pubertal (27.2%). All of them were in good clinical status and were not affected by any nonthyroidal illnesses. No patients exhibited either palpable goiter or symptoms generally associated with thyroid hypofunction. Thyroid ultrasonography (US) was normal and thyroid autoimmunity was negative in all the cases at the time of admission. None of them was taking iodinated drugs, lithium salts, glucocorticoids or antiepileptic agents. Clinical history of all the patients did not evidence any antecedents of either neck radiation therapy or false positivity at congenital hypothyroidism screening. The study was performed in non-iodine deficient areas. Therefore, in the entire study population all the etiological causes of SH had been excluded at the time of admission.

All these patients with “idiopathic” SH were studied as outpatients. SH was defined by elevated TSH concentrations (5 – 10 mU/l) in the presence of normal FT4 concentrations (10.3 – 24.4 pm/L). Two measurements of these hormones with an interval of 1 - 3 months were required to enter in the
follow-up period. Patients were prospectively evaluated 6, 12 and 24 months after their admission and at each visit clinical and hormonal (TSH and FT4) data and thyroid autoimmunity status were assessed. Thyroid US was re-evaluated at the end of 24-month follow-up in all the patients. In the patients who exhibited during follow-up a further increase of TSH levels above 10 mU/l, at the end of follow-up, L-T4 treatment was begun, according to our guidelines (8) and other recommendations (9).

**Methods**

Thyroid function tests were determined in the fasting status and performed in the same Laboratory for each subject. TSH and FT4 were determined by high specific fluorometric immunoassays. Intra- and inter-assay variations were less than 10%.

Thyroid autoimmunity was studied by the measurement of serum levels of thyroid peroxidase antibodies (TPOAb) and the titer was considered positive for values higher than 20 U/ml.

Thyroid US was performed in all subjects with a high resolution 7.5 MHz linear transducer. The analysis of thyroid volume and echogenicity in each patient was assessed by the same operator both at entry and at the end of follow-up.

Clinical evaluation aimed to ascertain the existence of symptoms and/or signs of hypothyroidism.

Auxological assessment was based on height (H) measurement and body mass index (BMI) calculation.

Standing H was measured with a Harpenden stadiometer (Holtain Ltd., Crymych, Dyfed, UK). BMI was calculated as weight divided by squared height (kg/m2). To allow the comparison between different ages and
genders, H and BMI were expressed as SD scores (SDS) according to the standards assessed by Cacciari et al (10).

**Statistical analysis**

Results are expressed as mean values; variability is indicated by SD and/or value range. For comparisons of two means, the Student’s t-test (normally distributed data) and the Mann-Whitney U test (non-parametric data) were used. Frequency rates were compared by Chi-square test. Correlations between quantitative variables were assessed using Pearson’s correlation analysis. The level of significance was set at 0.05.

This study design was approved by the Ethical Committees of our Hospitals and patients and/or their parents gave their informed consent. Appropriate consents for this study were also obtained from the Study Group for Thyroid Diseases of the Italian Society for Pediatric Endocrinology and Diabetology.

**RESULTS**

**Changes in thyroid tests during follow-up**

Average initial TSH concentrations significantly lowered during the first 6 months of follow-up and still further during the subsequent months (Table 1). The mean decrement in TSH concentrations from baseline to the end of follow-up was 1.0 ± 2.1 mU/l. TSH decrement in the overall series was unrelated to either sex or age or pubertal status or concomitant FT4 changes. Mean FT4 levels did not significantly change throughout follow-up period (Table 1). In all the patients FT4 levels remained within normal range at each time.

Thyroid US at the end of observation period revealed significant changes compatible with Hashimoto’s thyroiditis in only 2 patients, whilst in the remaining ones no significant alterations were found. TPOAb remained
undetectable during the entire follow-up in all patients but two, i.e. the same two with US changes.

**TSH normalization**

On overall 38/92 patients normalized their TSH concentrations (<5mU/l) during the 2-year observation period (Group A): none during the first 6 months, sixteen between 6 and 12 months and twenty-two between 12 and 24 months (Table 2).

The fall in TSH values was similar in early and late normalizers. Only 2 patients (5.3%) reverted to TSH values lower than 2 mU/l, whilst most normalizers (68.4%) achieved TSH levels between 3 and 4.3 mU/l.

Among the remaining 54 patients who did not normalize TSH concentrations during the observation period (58.7%), the majority maintained their TSH within the baseline limits (5-10 mU/l) during the entire follow-up (Group B), whereas 11 exhibited a further increase of TSH levels above 10 mU/l (between 10.5 and 15.0) despite persistently normal FT4 levels and underwent L-T4 therapy after the end of follow-up according to our study design (Group C). In two of these 11 patients TSH increase was accompanied by both TPOAb detection and thyroid US features of Hashimoto thyroiditis at the end of follow-up.

The percentages of patients with either decreasing or increasing or stable TSH values are scheduled in Table 2.

**Factors influencing TSH normalization**

Average baseline TSH concentrations (6.0 ± 1.5 vs 6.2 ± 1.1 mU/l) were very similar in the patients who normalized their TSH during follow-up compared with those with persistent hyperthyreotropinemia. Even in the patients of Group C, both TSH and FT4 at study entry (6.0 ± 1.2 mU/l and
15.6 ± 3.8 pm/l respectively) were not significantly different with respect to those of Group B (6.2 ± 1.1 and 14.8 ± 3.4 respectively) and A (6.0 ± 1.5 and 13.6 ± 3.4 respectively).

Patients who normalized their TSH late (24 months) showed higher initial TSH levels (6.2 ± 1.7 vs 5.8 ± 1.3 mU/l, p < 0.0125) and lower initial FT4 levels (12.9 ± 3.3 vs 14.7 ± 3.3 pm/l, p < 0.05) with respect to those who showed early normalization (12 months). However, even the patients who normalized late their TSH exhibited a significant decrease of TSH values from baseline to 12 months (from 6.2 ± 1.7 to 5.0 ± 1.6 mU/l, p < 0.05), whereas no significant decrease from baseline to 12 months was observed in the patients who did not normalize their TSH during the entire follow-up.

The prevalence of patients who normalized their TSH during follow-up period was significantly higher in the pubertal patients than in the prepubertal ones (64.0 vs 34.3%; $\chi^2 = 5.7$, p < 0.01), whilst no differences were found between boys and girls (40.0 vs 42.8 %; $\chi^2 = 0.1$, p > 0.05).

At the end of follow-up the prevalences of pubertal patients in Group A (57.9%) and B (23.2%) were not significantly different if compared with the one found in Group C (36.4%).

On overall TSH values at the time of normalization did not significantly correlate with either the corresponding values of FT4 or the time at normalization.

The prevalence of familial antecedents of thyroid diseases was not significantly different in the patients who normalized TSH than in the ones with no TSH normalization (45.8 vs 54.2%; $\chi^2 = 1.6$, p > 0.05).

Clinical and auxological data
None of the patients showed any clinical signs or symptoms of hypothyroidism during the entire follow-up.

During follow-up no significant changes in the average H and BMI SDS were longitudinally observed in the entire study population and in the different Groups as reported in Table 3. Both at entry and at the end of follow-up the percentages of individuals with height deficiency were not significantly different in the entire series and in the 3 subgroups (Table 3).

In the overall study population the percentage of individuals with overweight significantly decreased from entry to the end of follow-up and this decrease was observed in both Group B ($\chi^2=5.5$, $p<0.01$) and in Group A, although Group A it did not achieve a statistical relevance ($\chi^2=2.3$, $p>0.05$) (Table 3). By contrast, in Group C the percentage of individuals with overweight remained stable from entry onwards (Table 3). At the end of follow-up the percentage of individuals with overweight was slightly higher in Group C with respect to the one found in the remaining 81 patients (36.4% vs 16%), but this difference did not achieve a statistical relevance ($\chi^2=2.6$, $p>0.05$).

Data concerning the longitudinal evolution of pubertal stages, height and BMI SDS during the entire follow-up in the patients of Group C are analytically reported in Table 4. An evolution of pubertal stages throughout the 2-year follow-up was found in the 4 patients who had already entered puberty at the beginning of the study (nos. 4,8,9 and 10), whilst the remaining 7 patients remained prepubertal during the entire follow-up (Table 4). The average height SDS at the end of follow-up did not significantly differ with respect to that recorded at study entry. In the 2 patients who exhibited a severe height deficiency at the end of study period,
height deficiency was already present at entry (nos. 4 and 8 of Table 4). Even BMI SDS did not significantly change from entry onwards. Three patients were obese at study entry (nos. 2, 3 and 6 of Table 4) but BMI did not change during the follow-up.

**DISCUSSION**

To the best of our knowledges this is the first study aiming to prospectively investigate the spontaneous evolution over time of pituitary-thyroid function in a selected series of children and adolescents with idiopathic SH. With respect to previous studies on young (3-7) or old patients (11-14), our study design is peculiar in that we have preliminarily excluded all the underlying diseases and the risk factors which are known to be able to affect the natural course of SH (3-7).

According to our results the natural history of TSH serum levels in a pediatric population with idiopathic SH is characterized by their progressive decrease over time, with no concomitant changes of FT4 values. This two-year prospective study shows that 38 patients (41.3%) of a cohort of 92 patients under age 15 years normalized their TSH values during follow-up and that only 11 of them (12%) underwent a deterioration of thyroid function, as demonstrated by an increase of TSH values in the range 10-15 mU/l. The risk of developing autoimmune thyroiditis in our series was unremarkable (2.2%).

On overall this favourable evolution was more evident in the pubertal patients than in the prepubertal ones, whilst it was not significantly affected by either sex, or FT4 levels or familial antecedents of thyroid diseases. In the overall study population these changes of TSH serum concentrations
over time were not associated with significant changes of clinical status and/or auxological parameters.

Our results as a whole allow us to confirm, on a larger series of patients, the conclusions by Moore (3) that juvenile SH is a benign and remitting process with a very low risk of evolution towards frank hypothyroidism. On the contrary, our results differ in some aspects from the ones previously reported in elderly patients with SH. In fact, Parle et al investigated the evolution of 73 patients aged 60 years and found that 18% developed overt hypothyroidism and only 5% reverted to normal TSH values, although the follow-up period was only 12 months (13). Huber et al studied a cohort of 82 women with a mean age of 50 years over a mean observation period of 9 years and found that 28% of them developed overt hypothyroidism, but only 4% became normal (11). The greater percentage of TSH normalization found in our survey may be explained by both the absence of previous history of either thyroid or nonthyroidal diseases and the only mild SH of all subjects, that showed TSH values ranging between 5 and 10 mU/l. In fact high baseline TSH levels, the presence of goiter and positive thyroid autoantibodies have been demonstrated to be the main risk factors for the progression to thyroid failure (11,13). It is not surprising, therefore, that a high percentage of reversion to normal TSH was also reported by Diez et al, who adopted a study design similar to the present one, by investigating only patients with mild thyroid hypofunction and no previous thyroid illnesses (2).

Nevertheless its to be underlined that in our series only a minority of patients (5.3%) reverted to TSH values lower than 2 mU/l, whereas most normalizers (68.4%) achieved TSH levels between 3 and 4.3 mU/l, a result
very similar to the one recently reported by Diez et al (12). The short duration of follow-up in the present study, however, does not allow us to predict the long-term evolution of these patients. In the early normalizers of the present study TSH normalization was confirmed 12 months later, i.e. at the end of follow-up period. However, to further characterize the spontaneous evolution of SH in children, more prolonged follow-up studies are necessary.

Finally, in our series both early and late normalizers exhibited an early decrease of TSH, whereas no significant decrease from baseline to 12 months was recorded in the patients who did not normalize at all their TSH. Early or late occurrence of TSH normalization in our study population was mainly conditioned by baseline TSH and FT4 levels.

Among the possible factors influencing the interindividual variations of serum TSH, mutations and polymorphisms that occur in the genes encoding the proteins involved in the TSH pathway could play a significant role. In this regard, the direct involvement of TSH receptor (TSHR) gene in the serum TSH concentration has been proven in some cases of SH, in which loss of function mutations has been identified (15,16). However, a low prevalence of TSHR mutations has been recently reported in children with SH (17). In the present series we did not examine TSHR gene because this was not the aim of our study.

In conclusion: a) the natural course of TSH values in a pediatric population with idiopathic SH is characterized by a progressive decrease over time; b) the majority of patients (88%) normalized or maintained unchanged their TSH; c) TSH changes were not associated with any changes of either FT4 values or clinical status or auxological parameters; d) TSH determination
has no reason to be part of routine check-up in children, apart from specific protocols.

Acknowledgement

This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.
REFERENCES


with mild hyperthyrtropinemia at neonatal screening for congenital hypothyroidism. *Journal of Clinical Endocrinology and Metabolism* 2008 Apr 29 [Epub ahead of print].


Tables’ Legends

Table 1
Changes in average (±SD) TSH and FT4 concentrations at various times during the entire follow-up in the overall study population.

Table 2
Percentages of patients who normalized their TSH (<5 mU/l) at various times during follow-up (Group A), of the ones who maintained their TSH within the initial 5-10 mU/l limits (Group B) and of those who exhibited an increase of TSH values above 10 mU/l (Group C).

Table 3
Average height (H) and body mass index (BMI) SDS and percentages of individuals with either severe height deficiency (<-2 SDS) or overweight (>90th percentile) at entry and at the end of follow-up in the overall study population and in the three subgroups with different TSH pattern during follow-up period.

Table 4
Pubertal stages, height and body mass index (BMI) both at entry and at the end of follow-up (lower panel) in the 11 patients of our series who exhibited TSH values >10 mU/l during follow-up (Group C).
Table 1

Changes in average (±SD) TSH and FT4 concentrations at various times during the entire follow-up in the overall study population.

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>6 mths</th>
<th>12 mths</th>
<th>24 mths</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TSH (mU/l)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>6.1 ± 1.3</td>
<td>5.4 ± 1.8*</td>
<td>5.3 ± 2.4*</td>
<td>4.7 ± 1.4*</td>
</tr>
<tr>
<td><strong>FT4 (pm/l)</strong></td>
<td>14.3 ± 3.4</td>
<td>14.2 ± 3.1</td>
<td>14.0 ± 3.5</td>
<td>14.0 ± 2.5</td>
</tr>
</tbody>
</table>

*p < 0.01 versus baseline TSH
Table 2

Percentages of patients who normalized their TSH (<5 mU/l) at various times during follow-up (Group A), of the ones who maintained their TSH within the initial 5-10 mU/l limits (Group B) and of those who exhibited an increase of TSH values above 10 mU/l (Group C).

<table>
<thead>
<tr>
<th></th>
<th>6 mths</th>
<th>12 mths</th>
<th>24 mths</th>
<th>On overall</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Group A (%)</strong></td>
<td>0</td>
<td>17.4</td>
<td>23.9</td>
<td>41.3</td>
</tr>
<tr>
<td><strong>Group B (%)</strong></td>
<td>100</td>
<td>83.6</td>
<td>46.7</td>
<td>46.7</td>
</tr>
<tr>
<td><strong>Group C (%)</strong></td>
<td>0</td>
<td>0</td>
<td>12.0</td>
<td>12.0</td>
</tr>
</tbody>
</table>
Table 3

Average height (H) and body mass index (BMI) SDS and percentages of individuals with either severe height deficiency (<-2 SDS) or overweight (>90th percentile) at entry and at the end of follow-up in the overall study population and in the three subgroups with different TSH pattern during follow-up period.

<table>
<thead>
<tr>
<th></th>
<th>Overall (n= 92)</th>
<th>Group A (n=38 )</th>
<th>Group B (n=43 )</th>
<th>Group C (n=11)</th>
</tr>
</thead>
<tbody>
<tr>
<td>H at study entry</td>
<td>-0.1±1.3</td>
<td>0.1±1.2</td>
<td>-0.2±1.4</td>
<td>-0.7±1.2</td>
</tr>
<tr>
<td>H at study end</td>
<td>-0.1±1.3</td>
<td>-0.1±1.2</td>
<td>0.0±1.5</td>
<td>-0.9±1.1</td>
</tr>
<tr>
<td>BMI at study entry</td>
<td>0.6±1.7</td>
<td>1.1±1.5</td>
<td>0.3±1.8</td>
<td>0.8±1.7</td>
</tr>
<tr>
<td>BMI at study end</td>
<td>1.0±3.3</td>
<td>1.8±4.4</td>
<td>0.2±1.3</td>
<td>0.9±1.6</td>
</tr>
<tr>
<td>% patients with H deficiency at study entry</td>
<td>8.7</td>
<td>2.6</td>
<td>11.6</td>
<td>18.2</td>
</tr>
<tr>
<td>% patients with H deficiency at study end</td>
<td>3.3</td>
<td>0</td>
<td>2.3</td>
<td>18.2</td>
</tr>
<tr>
<td>% patients with overweight at study entry</td>
<td>34.8</td>
<td>36.8</td>
<td>32.6</td>
<td>36.4</td>
</tr>
<tr>
<td>% patients with overweight at study end</td>
<td>18.5</td>
<td>8.7</td>
<td>5.4</td>
<td>36.4</td>
</tr>
</tbody>
</table>
Table 4

Pubertal stages, height and body mass index (BMI) both at entry and at the end of follow-up (lower panel) in the 11 patients of our series who exhibited TSH values >10 mU/l during follow-up (Group C).

<table>
<thead>
<tr>
<th>Patients</th>
<th>Pubertal stages</th>
<th>Height (SDS)</th>
<th>BMI (SDS)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>At study entry</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>B1P1</td>
<td>-0.06</td>
<td>-1.2</td>
</tr>
<tr>
<td>2</td>
<td>G1P1</td>
<td>0.2</td>
<td>2.7</td>
</tr>
<tr>
<td>3</td>
<td>B1P1</td>
<td>1.3</td>
<td>2.32</td>
</tr>
<tr>
<td>4</td>
<td>B3P2</td>
<td>-2.5</td>
<td>-1.9</td>
</tr>
<tr>
<td>5</td>
<td>G1P1</td>
<td>-1.8</td>
<td>-1.07</td>
</tr>
<tr>
<td>6</td>
<td>G1P1</td>
<td>0.28</td>
<td>3.35</td>
</tr>
<tr>
<td>7</td>
<td>G1P1</td>
<td>-0.08</td>
<td>0.88</td>
</tr>
<tr>
<td>8</td>
<td>G1P2</td>
<td>-2.2</td>
<td>1.1</td>
</tr>
<tr>
<td>9</td>
<td>G2P2</td>
<td>-1.4</td>
<td>0.9</td>
</tr>
<tr>
<td>10</td>
<td>G2P3</td>
<td>-0.28</td>
<td>1.34</td>
</tr>
<tr>
<td>11</td>
<td>B1P1</td>
<td>-1.0</td>
<td>0.5</td>
</tr>
<tr>
<td><strong>Mean ± SD</strong></td>
<td></td>
<td>-0.7 ± 1.2</td>
<td>0.8 ± 1.7</td>
</tr>
</tbody>
</table>

| **At the end of the follow-up** | | | |
| 1        | B1P1            | -0.5         | -1.4      |
| 2        | G1P1            | -0.2         | 2.7       |
| 3        | B1P1            | 1.0          | 2.3       |
| 4        | B5P5            | -2.5         | -1.6      |
| 5        | G1P1            | -1.9         | -0.6      |
| 6        | G1P1            | 0.2          | 3.5       |
| 7        | G1P1            | -0.2         | 1.3       |
| 8        | G4P4            | -2.3         | 1.2       |
| 9        | G5P5            | -1.4         | 1.0       |
| 10       | G5P5            | -0.7         | 0.8       |
| 11       | B1P1            | -1.2         | 0.5       |
| **Mean ± SD** | | -0.9 ± 1.1 | 0.9 ± 1.6 |